We develop next generation nucleic acid-based therapies using our proprietary Fusogenix drug delivery system.
Fusogenix uses a novel mechanism of action to deliver molecules, intact and unmodified, directly into the cytosol of target cells. The technology is applicable to a wide range of nucleic acid medicines.
“Based on the preclinical in vivo safety and efficacy data, we believe our Fusogenix DNA vaccine candidates have the potential to be safe and highly potent vaccines that will provide protection against COVID-19 as well as future coronavirus threats.”
Dr. John Lewis, CEO Entos Pharmaceuticals
Fusogenix is the ideal platform for delivery of next generation genetic therapies.
Unlike conventional lipid-based delivery, Fusogenix is well tolerated at high systemic doses, and retains maximal activity with repeat dosing. Entos has developed unique formulations to effectively deliver a wide range of genetic therapies, including gene therapy, mRNA, miRNA, RNAi and CRISPR.
Fusogenix has a wide biodistribution across all organs and tissues.
Due to the unique biophysical and chemical properties of Fusogenix a wide variety of extra-hepatic tissues can be effectively targeted at therapeutic doses. Entos has developed a panel of formulations to accurately target specific tissues.
Fusogenix uses a novel fusion mechanism to deliver its payload directly inside cells.
Our proprietary FAST (Fusion-Associated Small Transmembrane) protein technology enables fusion of the proteo-lipid vehicle with the plasma membrane of target cells. Nucleic acid cargoes are delivered intact into the cytoplasm for immediate use as a therapeutic agent.